ST6GAL1 and familial pancreatic carcinoma: Since Martin et al. reported that there was no significant histological abnormality in the organs of ST6Gal1 null mice [42], we anticipate that sialyltransferase ST6Gal1 can serve as a potential target for future pancreatic cancer therapeutics development.